A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

Caroline C Øhrstrøm, Dorte L Hansen, Urd Lynge Kielgast, Bolette Hartmann, Jens Juul Holst, Dorte Worm

8 Citations (Scopus)

Abstract

Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.

Original languageEnglish
JournalObesity Surgery
Volume30
Issue number4
Pages (from-to)1605-1610
Number of pages6
ISSN0960-8923
DOIs
Publication statusPublished - Apr 2020

Keywords

  • Gastric bypass
  • Hyperglycemia
  • Hypoglycemia
  • Pasireotide
  • Somatostatin analogs

Fingerprint

Dive into the research topics of 'A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals'. Together they form a unique fingerprint.

Cite this